Ipsen, a global specialty-driven pharmaceutical company, has reported its fourth quarter and full year results with total sales exceeding €1.1bn in 2011.
The company said in the major Western European countries including Germany and Spain, total group sales accounted to 46.7% at the end of 2011, compared to 50% a year earlier.
While in other European countries, such as Switzerland, sales amounted to €279.6m in 2011, which is up 8.5% year-on-year excluding foreign exchange impacts.
For the fourth quarter 2011, sales generated in the other European countries reached €68.4m, up 33.4% year-on-year and in major Western European countries amounted to €136.4m, down 1.7% year-on-year.
In 2011, sales generated in North America reached €65.7m, up 15.3% year-on-year, fuelled by the continuous penetration of Somatuline in acromegaly and Dysport in cervical dystonia.
Ipsen's sales generated in the rest of the world reached €272.5m in 2011, up 15.4% year-on-year, driven by strong volume growth in China, Brazil, Australia and Algeria, and the fourth quarter 2011, sales reached €72.7m, up 38.6% year-on-year.
For the full year 2011, group drug sales increased by 5.7% year-on-year excluding foreign exchange impacts, while consolidated group sales reached €1,159.8m, which is up 5.4% year-on-year excluding foreign exchange impacts.
Ipsen chairman and CEO, Marc de Garidel, said: "With 5.7% up in drug sales, the company has delivered a very strong sales performance, driven by the sustained growth of specialty care, the resilience of primary care in 2011 and also showed 9.9% increase in the very dynamic international drug sales excluding foreign exchange impacts."
Garidel added: "Lastly, Ipsen and Inspiration will work closely together to prepare the launch of Ixinity (IB1001) in Europe. 2012 will be an important transition year to meet the group's 2020 ambition."